Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "SIFI"

256 News Found

Agilent presents 2023 Darlene Solomon Award to Kathryn Wolhuter
People | March 28, 2023

Agilent presents 2023 Darlene Solomon Award to Kathryn Wolhuter

The award recognizes and supports promising female scientists working in mass spectrometry


Investment in healthcare workforce key to accelerating India’s economic growth: Experts
Healthcare | March 23, 2023

Investment in healthcare workforce key to accelerating India’s economic growth: Experts

Integration of modern and traditional medicine to facilitate the illness to wellness journey


Zydus granted Orphan Drug Designation by USFDA for ZYIL1
Drug Approval | March 22, 2023

Zydus granted Orphan Drug Designation by USFDA for ZYIL1

ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates


Jubilant Pharmova receives VAI from USFDA for its API manufacturing facility
Drug Approval | March 09, 2023

Jubilant Pharmova receives VAI from USFDA for its API manufacturing facility

Based on this inspection and the USFDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP)


Mandaviya focuses on high value pharmaceuticals and high-end medical devices to reduce the import dependency
Policy | February 22, 2023

Mandaviya focuses on high value pharmaceuticals and high-end medical devices to reduce the import dependency

First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals


Aarti Drugs Q3 FY23 revenue grows 4%
News | January 28, 2023

Aarti Drugs Q3 FY23 revenue grows 4%

Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY


USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions
Drug Approval | January 17, 2023

USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions

The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22


USFDA conducts PAI and GMP inspection of Piramal Pharma's Sellersville facility
Drug Approval | January 16, 2023

USFDA conducts PAI and GMP inspection of Piramal Pharma's Sellersville facility

The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations